Targeting Tumor Cells with Nanoparticles for Enhanced Co-Drug Delivery in Cancer Treatment

Pharmaceutics

Po-Hung Hsu¹  Wen-Ying Huang²  Shin-Lei Peng³  Pei-Yi Chu⁴  Che-Yu Hsu⁴  Yu-Hsin Lin⁴  Chun-Lung Feng⁵  Chih-Ho Lai⁶ 

[1] Center for Advanced Molecular Imaging and Translation, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan;Department of Applied Cosmetology, Hung-Kuang University, Taichung 433304, Taiwan;Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung 404, Taiwan;Department of Pharmacy, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan;Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung 404332, Taiwan;Molecular Infectious Disease Research Center, Department of Microbiology and Immunology, Chang Gung University and Chang Gung Memorial Hospital, Taoyuan 333323, Taiwan;

关键词: gastric cancer;    nanoparticle;    fucoidan;    d-alpha-tocopherylpoly (ethylene glycol) succinate;    combination chemotherapy;   

DOI  :  10.3390/pharmaceutics13091327

来源: DOAJ

【 摘 要 】

Gastric cancer (GC) is a fatal malignant tumor, and effective therapies to attenuate its progression are lacking. Nanoparticle (NP)-based solutions may enable the design of novel treatments to eliminate GC. Refined, receptor-targetable NPs can selectively target cancer cells and improve the cellular uptake of drugs. To overcome the current limitations and enhance the therapeutic effects, epigallocatechin-3-gallate (EGCG) and low-concentration doxorubicin (DX) were encapsulated in fucoidan and d-alpha-tocopherylpoly (ethylene glycol) succinate-conjugated hyaluronic acid-based NPs for targeting P-selectin-and cluster of differentiation (CD)44-expressing gastric tumors. The EGCG/DX-loaded NPs bound to GC cells and released bioactive combination drugs, demonstrating better anti-cancer effects than the EGCG/DX combination solution. In vivo assays in an orthotopic gastric tumor mouse model showed that the EGCG/DX-loaded NPs significantly increased the activity of gastric tumors without inducing organ injury. Overall, our EGCG/DX-NP system exerted a beneficial effect on GC treatment and may facilitate the development of nanomedicine-based combination chemotherapy against GC in the future.

【 授权许可】

Unknown